BiofronteraBFRI -2.92%44 Gross Margin % is 79.02% as of Mar. 2026, which is 58% above its 10-year median of 50.14. GuruFocus rates BFRI with a GF Score™ of 44/100 and a GF Value™ of $0.54 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 938 Drug Manufacturers companies, Biofrontera ranks better than 89.66% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Biofrontera's Gross Profit for the
three
months ended in Mar. 2026 was $7.97 Mil. Biofrontera's Revenue for the
three
months ended in Mar. 2026 was $10.08 Mil. Therefore, Biofrontera's Gross Margin % for the quarter that ended in Mar. 2026 was 79.02%.
The historical rank and industry rank for Biofrontera's Gross Margin % or its related term are showing as below:
BFRI'
s Gross Margin % Range Over the Past 10 Years
Min: 47.04 Med: 50.14 Max: 77.29
Current: 77.29
During the past 7 years, the highestGross Margin % of Biofrontera was 77.29%. The lowest was 47.04%. And the median was 50.14%.
BFRI's Gross Margin % is ranked better than 89.66% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.44
vs BFRI: 77.29
Biofrontera had a gross margin of 79.02% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Biofrontera was 5.80% per year.
Biofrontera (NAS:BFRI) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Biofrontera had a gross margin of 79.02% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Biofrontera Gross Margin % Related Terms
Biofrontera Gross Margin % Historical Data
* Premium members only.
The historical data trend for Biofrontera's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BFRI vs AKAN, CABR, BIOE: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Biofrontera's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Biofrontera (BFRI) has a Gross Margin % of 79.02% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Biofrontera and its competitors. This is 58% above median its historical median of 50.14. Over the past decade, Biofrontera's Gross Margin % has ranged from 47.04 to 77.29. According to the industry distribution chart, Biofrontera ranks #97 out of 938 companies in the Drug Manufacturers industry, placing it in the top 10.3%.
Is Biofrontera's Gross Margin % too high?
Biofrontera's current Gross Margin % of 79.02% is 58% above median its 10-year median of 50.14. Over the past 10 years, this metric has ranged from a low of 47.04 to a high of 77.29. The Drug Manufacturers industry median Gross Margin % is 48.44. Biofrontera's value of 79.02% is 63.1% above this industry median. Based on the distribution chart, Biofrontera ranks #97 out of 938 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biofrontera has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biofrontera's Gross Margin % compare to AKAN and CABR?
According to the Drug Manufacturers industry distribution chart, Biofrontera ranks #97 out of 938 companies for Gross Margin %. This places Biofrontera in the top 10% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.44. Biofrontera's value of 79.02% is 63.1% above this benchmark. Historically, Biofrontera's own Gross Margin % has ranged from 47.04 to 77.29 over the past decade. While the company's 10-year median is 50.14 vs. the industry median of 48.44, Biofrontera has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofrontera's current Gross Margin % of 79.02% is 63.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Biofrontera and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofrontera's current Gross Margin % is 79.02%, which is 58% above median its own 10-year median of 50.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera stock overvalued right now?
Based on GuruFocus' analysis, Biofrontera (BFRI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.54, compared to a current price of $1.00 — trading 85.2% above its estimated fair value. The current Gross Margin % is 79.02%, which is 58% above median its 10-year median of 50.14 and 63.1% above the Drug Manufacturers industry median of 48.44. Biofrontera's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Biofrontera (BFRI), the current Gross Margin % is 79.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofrontera (BFRI) Overvalued in 2026?
Based on GuruFocus' analysis, Biofrontera stock appears to be overvalued.
The current stock price of $1.00 is trading 85.2% above its estimated GF Value™ of $0.54.
GuruFocus considers Biofrontera to be Significantly Overvalued.
Key valuation signals for BFRI:
Gross Margin %: 79.02% (58% above median its 10-year median of 50.14)
GF Value™: $0.54 vs. price of $1.00 (85.2% above fair value)
Industry Position: 63.1% above the Drug Manufacturers median (#97 of 938)
No single metric tells the full story. See the BFRI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
44GF Score
Get the complete analysis for BFRI
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BFRI has been successfully added to your 
